Stock Report

All about this stock under one free report Last Updated: 16-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Blue Jet Health Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: BLUEJET | BSE: 544009

₹520.65

up-down-arrow ₹1.20 (0.23%)

As on 16-Oct-2026IST

Market cap

info icon

₹9,841 Cr

Revenue (TTM)

info icon

₹886 Cr

P/E Ratio

info icon

41.9

P/B Ratio

info icon

4.4

Div. Yield

info icon

0.2 %

Edit peer-selector-edit
Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 9,841 34,665 25,506 16,109 14,037
Revenue (₹ Cr)
 886 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 234.91 1,018.97 497.77 603.02 270.18
Net Margin (%)
 24.44 10.47 20.72 22.63 23.29
RoE (%)
 17.96 21.30 28.49 19.61 14.45
Price to Earnings
 41.89 34.27 51.24 26.71 50.98
Price-To-Book
 4.40 6.63 12.62 4.62 6.77

Income Statement (₹ Cr)

Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
947.32 9,203.54 2,022.99 2,551.83 1,054.89
Total Income arrow
1,015.98 9,335.01 2,053.15 2,612.24 1,107.25
Total Expenditure arrow
653.22 7,457.80 1,448.49 1,754.55 686.95
EBITDA arrow
294.10 1,745.74 574.50 797.28 367.94
Depreciation arrow
24.00 415.05 91.74 75.36 74.46
EBIT arrow
270.10 1,330.70 482.76 721.93 293.48
Interest arrow
6.24 143.67 23.95 5.37 0.82
Other Income arrow
68.65 131.47 30.17 60.41 52.36
Exceptional Items arrow
-- -31.35 76.40 -25.66 -3.28
Profit before Tax arrow
332.51 1,287.14 488.98 751.31 344.65
Provision for Tax arrow
84.70 345.87 124.98 186.83 85.42
Profit after Tax arrow
247.82 941.27 364.00 564.48 259.23

Liabilities (₹ Cr)

Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
1,359.91 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
-- 26.64 -- -- -1.92
Non-Current Liabilities arrow
350.27 584.19 345.47 142.73 47.58
Current Liabilities arrow
276.66 3,912.24 710.20 682.24 169.08
Total Liabilities arrow
1,986.84 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
980.60 3,861.01 1,447.01 1,333.54 981.68
Current Assets arrow
1,006.25 5,612.10 1,483.13 2,823.56 1,250.11
Total Assets arrow
1,986.84 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
0.00 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
729.59 1,699.86 772.93 2,141.33 1,081.03
Contingent Liabilities arrow
0.68 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
334.15 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-275.58 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
-30.69 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
27.88 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
27.18 25.25 27.50 24.61 18.04
ROE (%) arrow
19.88 20.09 21.43 18.41 13.54
ROA (%) arrow
13.58 10.70 14.25 14.27 12.15
EBIT Margin (%) arrow
38.29 20.40 29.89 33.61 39.84
Net Margin (%) arrow
24.39 10.08 17.73 21.61 23.41
Cash Profit Margin (%) arrow
28.69 14.44 22.53 24.81 31.63

Growth Ratios

 Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
-8.03 16.56 36.98 6.91 -12.10
EBIT Growth (%) arrow
-14.44 21.77 75.89 19.60 -23.76
Net Profit Growth (%) arrow
-18.80 33.05 39.94 16.24 -30.25
EPS Growth (%) arrow
-18.80 35.59 39.94 16.05 -29.80
Book Value Growth (%) arrow
20.02 11.36 22.95 18.43 11.27

Valuation Ratios

 Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
22.91 32.73 42.34 21.18 40.73
Price / Book Value arrow
4.17 6.13 8.23 3.60 5.27
Dividend Yield (%) arrow
0.37 0.23 0.28 0.51 0.74
EV/EBITDA arrow
15.24 16.68 25.23 13.94 25.25
Market Cap (₹ Cr) arrow
5,676.63 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.24 0.10 0.00 0.00
Short term debt to equity ratio arrow
-- 0.16 -- -- 0.00
Current Ratio arrow
3.64 1.43 2.09 4.14 7.39
Quick Ratio arrow
2.96 0.82 1.37 3.12 5.46
Interest Coverage arrow
54.30 9.96 21.42 140.86 419.57

Operating Efficiency Ratios

 Blue Jet Health Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
35.79 27.84 26.76 42.05 43.63
Asset Turnover arrow
0.52 1.07 0.79 0.65 0.49
Receivable days arrow
132.65 88.68 77.32 144.58 169.86
Inventory Days arrow
86.94 84.11 80.83 96.67 97.92
Payable days arrow
61.13 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
158.47 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...